Table 3.

Numbers and proportions of seroconversion (modified per protocol; n=466) after two doses of BNT162b2 vaccine in healthy controls and five different groups of immunocompromised patients.¹

	Controls	All immunocompromised patients	PID	HIV	HSCT	SOT	CLL
Seroconverted (n)	78	280	55	78	61	36	50
Seronegative (n)	0	108	20	1	11	47	29
Total (n)	78	388	75	79	72	83	79
Proportion of seroconverted (CI) (%), P-value	100 (95.4-100) Ref.	72.2 (67.4 – 76.6) P<0.001	73.3 (61.9-82.9) P<0.01	98.7 (93.1-100) P=1	84.7 (74.3-92.1) P<0.01	43.4 (32.5-54.7) P<0.01	63.3 (51.7-73.9) P<0.01

Abbreviations: PID: primary immunodeficiency, HIV: human immunodeficiency virus, HSCT, hematopoietic stem cell transplantation, SOT: solid organ transplantation, CLL: chronic lymphocytic leukemia, CTRL: healthy controls, CI: 95% confidence interval (estimated).

¹P-values of the differences vs. healthy controls were calculated, Fisher's exact test.